A Phase 3 interventional study of Maridebart cafraglutide and Semaglutide in Diabetes Mellitus, Type 2, sponsored by Amgen. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Diabetes Mellitus, Type 2 by Amgen — 3 open to participants now, 7 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Amgen.
Among the 16 studies in Diabetes Mellitus, Type 2 by Amgen, this one has the largest planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 3, and was the 16th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 16 studies in Diabetes Mellitus, Type 2 by Amgen are open now, in 5 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Canada, Japan and 2 more countries
Ages 18–99
Amgen · Sites in United States
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,300 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 221 across the 16 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
3 of the studies in Diabetes Mellitus, Type 2 by Amgen that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06987695Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease | 2027-04-27 |
| NCT07590193AmgenA Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus | 2027-10-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Diabetes Mellitus, Type 2 by Amgen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previous or planned (during the trial) surgical, endoscopic, or device-based treatment for obesity. The following are allowed:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive maridebart cafraglutide administered subcutaneously (SC) once every 4 weeks (Q4W) in a dose-escalation manner.
Drug: Maridebart cafraglutide
Participants will receive semaglutide administered SC once weekly (QW) in a dose-escalation manner.
Drug: Semaglutide
Administered subcutaneously.
Also known as: AMG 133, MariTide
Administered subcutaneously.
Change from Baseline in Hemoglobin A1c (HbA1c) at Week 68 [Non-inferiority]
Time frame: Baseline to Week 68
Change from Baseline in HbA1c at week 68 [Superiority]
Time frame: Baseline to Week 68
Percent Change from Baseline in Body Weight at Week 68
Time frame: Baseline to Week 68
Percentage of Participants Achieving HbA1c < 7.0% at Week 68
Time frame: Week 68
Percentage of Participants Achieving HbA1c ≤ 6.5% at Week 68
Time frame: Week 68
Percentage of Participants Achieving HbA1c < 5.7% at Week 68
Time frame: Week 68
Change from Baseline in Fasting Plasma Glucose at Week 68
Time frame: Baseline to Week 68
Percentage of Participants Achieving ≥ 5% Reduction in Body Weight from Baseline at Week 68
Time frame: Baseline to Week 68
Percentage of Participants Achieving ≥ 10% Reduction in Body Weight from Baseline at Week 68
Time frame: Baseline to Week 68
Percentage of Participants Achieving ≥ 15% Reduction in Body Weight from Baseline at Week 68
Time frame: Baseline to Week 68
Percentage of Participants Achieving HbA1c ≤ 6.5% and Weight Reduction ≥ 10% from Baseline at Week 68
Time frame: Baseline to Week 68
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Up To 81 Weeks
Number of Participants Experiencing ≥ Level 2 American Diabetes Association (ADA) Defined Hypoglycemic Episodes
Time frame: Up To 81 Weeks
Plasma Concentration of Maridebart Cafraglutide at Week 68
Time frame: Week 68
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Started Oct 2026 (actual). Primary completion is estimated for Sep 2028, 22 months after the start.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 22 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maridebart cafraglutide